{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:32:53Z","timestamp":1793201573905,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Early detection of neuromyelitis optica spectrum disorders (NMOSD), especially after optic neuritis, a presenting manifestation commonly observed also in multiple sclerosis (MS), is crucial for timely treatment and prognosis. Integrated visual pathway assessment with optical coherence tomography (OCT) and visual evoked potentials (VEP) may help in this task, showing\n                    <jats:italic>in vivo<\/jats:italic>\n                    different pathophysiological backgrounds. We evaluated combined VEP and OCT in a cross-sectional, single-centre study assessing 50 consecutive NMOSD patients, 57 MS patients and 52 healthy controls. After optic neuritis, VEP were more frequently absent in NMOSD compared to MS; most NMOSD eyes with recordable VEP showed prolonged latency, but extreme latency delays were less common than in MS. OCT showed predominantly axonal involvement in NMOSD, with 88% eyes (95% CI: 69\u201397%) displaying retinal nerve fibre layer thickness &lt;60\u2009\u00b5m even after first optic neuritis episode. Accuracy of OCT was further enhanced by combination with VEP into a new Z-score derived OCT-VEP index, measuring prevalence of axonal damage or demyelination. Our results suggest that integrated optic nerve assessment may elucidate differences in optic neuritis pathophysiology; conduction slowing with relatively preserved nerve fibre layer suggests MS, while severe neuroaxonal loss after optic neuritis, often hindering VEP response, characterizes NMOSD.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-46251-3","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T06:02:43Z","timestamp":1563343363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis"],"prefix":"10.1038","volume":"9","author":[{"given":"Marco","family":"Vabanesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Guerrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Medaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Leocani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"key":"46251_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1212\/WNL.0b013e3181af78b8","volume":"73","author":"JN Ratchford","year":"2009","unstructured":"Ratchford, J. N. et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology. 73, 302\u2013308 (2009).","journal-title":"Neurology."},{"key":"46251_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/WNL.0b013e3181aaea32","volume":"73","author":"RT Naismith","year":"2009","unstructured":"Naismith, R. T. et al. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology. 73, 46\u201352 (2009).","journal-title":"Neurology."},{"key":"46251_CR3","doi-asserted-by":"publisher","first-page":"e66151","DOI":"10.1371\/journal.pone.0066151","volume":"8","author":"E Schneider","year":"2013","unstructured":"Schneider, E. et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS ONE. 8, e66151 (2013).","journal-title":"PLoS ONE."},{"key":"46251_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ophtha.2012.07.066","volume":"120","author":"DB Fernandes","year":"2013","unstructured":"Fernandes, D. B. et al. Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology. 120, 387\u2013394 (2013).","journal-title":"Ophthalmology."},{"key":"46251_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/brain\/awr264","volume":"135","author":"SB Syc","year":"2012","unstructured":"Syc, S. B. et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. 135, 521\u2013533 (2012).","journal-title":"Brain."},{"key":"46251_CR6","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1212\/WNL.0b013e31828c2f7a","volume":"80","author":"ES Sotirchos","year":"2013","unstructured":"Sotirchos, E. S. et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology. 80, 1406\u20131414 (2013).","journal-title":"Neurology."},{"key":"46251_CR7","first-page":"920","volume":"65","author":"J de Seze","year":"2008","unstructured":"de Seze, J. et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol. 65, 920\u2013923 (2008).","journal-title":"Arch Neurol."},{"key":"46251_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/WNO.0b013e31829c510e","volume":"33","author":"AP Lange","year":"2013","unstructured":"Lange, A. P. et al. Spectral-domain optical coherence tomography of retinal nerve fiber layer thickness in NMO patients. J Neuroophthalmol. 33, 213\u2013219 (2013).","journal-title":"J Neuroophthalmol."},{"key":"46251_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jns.2009.02.371","volume":"281","author":"A Watanabe","year":"2009","unstructured":"Watanabe, A. et al. Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients. J Neurol Sci. 281, 34\u201340 (2009).","journal-title":"J Neurol Sci."},{"key":"46251_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/1352458512447597","volume":"19","author":"SP Neto","year":"2013","unstructured":"Neto, S. P. et al. Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica. Mult Scler. 19, 173\u2013178 (2013).","journal-title":"Mult Scler."},{"key":"46251_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/1352458513503053","volume":"20","author":"M Ringelstein","year":"2014","unstructured":"Ringelstein, M. et al. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler. 20, 617\u2013620 (2014).","journal-title":"Mult Scler."},{"key":"46251_CR12","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458514567216","volume":"21","author":"J Bennett","year":"2015","unstructured":"Bennett, J. et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler. 21, 678\u2013688 (2015).","journal-title":"Mult Scler."},{"key":"46251_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1212\/WNL.0b013e31827deb39","volume":"80","author":"A Klistorner","year":"2013","unstructured":"Klistorner, A. et al. Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential. Neurology. 80, 242\u2013245 (2013).","journal-title":"Neurology."},{"key":"46251_CR14","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1177\/1352458514523498","volume":"20","author":"D Narayanan","year":"2014","unstructured":"Narayanan, D. et al. Tracking changes over time in retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in multiple sclerosis. Mult Scler. 20, 1331\u20131341 (2014).","journal-title":"Mult Scler."},{"key":"46251_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 69, 292\u2013302 (2011).","journal-title":"Ann Neurol."},{"key":"46251_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 85, 177\u2013189 (2015).","journal-title":"Neurology."},{"key":"46251_CR17","unstructured":"International Council of Ophthalmology (ICO). Visual Acuity Measurement Standard. Italian J Ophthalmol. II\/I, 1\u201315 (1988)."},{"key":"46251_CR18","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","volume":"86","author":"A Cruz-Herranz","year":"2016","unstructured":"Cruz-Herranz, A. et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 86, 2303\u20132309 (2016).","journal-title":"Neurology."},{"key":"46251_CR19","doi-asserted-by":"publisher","first-page":"e34823","DOI":"10.1371\/journal.pone.0034823","volume":"7","author":"P Tewarie","year":"2012","unstructured":"Tewarie, P. et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE. 7, e34823 (2012).","journal-title":"PLoS ONE."},{"issue":"1","key":"46251_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10633-009-9195-4","volume":"120","author":"JV Odom","year":"2010","unstructured":"Odom, J. V. et al. ISCEV standard for clinical visual evoked potentials (2009 update). Doc Ophthalmol. 120(1), 111\u2013119 (2010).","journal-title":"Doc Ophthalmol."},{"key":"46251_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/WNO.0b013e31825662f1","volume":"32","author":"MJ Morrow","year":"2012","unstructured":"Morrow, M. J. & Wingerchuk, D. Neuromyelitis optica. J Neuroophthalmol. 32, 154\u2013166 (2012).","journal-title":"J Neuroophthalmol."},{"key":"46251_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","volume":"88","author":"I Kawachi","year":"2017","unstructured":"Kawachi, I. & Lassmann, I. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 88, 137\u2013145 (2017).","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"46251_CR23","doi-asserted-by":"publisher","first-page":"e102546","DOI":"10.1371\/journal.pone.0102546","volume":"9","author":"P Sriram","year":"2014","unstructured":"Sriram, P. et al. Relationship between optical coherence tomography and electrophysiology of the visual pathway in non-optic neuritis eyes of multiple sclerosis patients. PLoS ONE. 9, e102546 (2014).","journal-title":"PLoS ONE."},{"key":"46251_CR24","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1111\/aos.12215","volume":"92","author":"KA Park","year":"2014","unstructured":"Park, K. A., Kim, J. & Oh, S. Y. Analysis of spectral domain optical coherence tomography measurements in optic neuritis: differences in neuromyelitis optica, multiple sclerosis, isolated optic neuritis and normal healthy controls. Acta Ophthalmol. 92, e57\u2013e65 (2014).","journal-title":"Acta Ophthalmol."},{"key":"46251_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S1474-4422(10)70168-X","volume":"9","author":"A Petzold","year":"2010","unstructured":"Petzold, A. et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 9, 921\u2013932 (2010).","journal-title":"Lancet Neurol."},{"key":"46251_CR26","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ana.24608","volume":"79","author":"M Hokari","year":"2016","unstructured":"Hokari, M. et al. Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol. 79, 605\u2013624 (2016).","journal-title":"Ann Neurol."},{"key":"46251_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","volume":"93","author":"R Dutta","year":"2011","unstructured":"Dutta, R. & Trapp, B. D. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol. 93, 1\u201312 (2011).","journal-title":"Prog Neurobiol."},{"key":"46251_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ophtha.2018.06.022","volume":"126","author":"T Shen","year":"2019","unstructured":"Shen, T. et al. Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Ophthalmol. 126, 445\u2013453 (2019).","journal-title":"Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46251-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46251-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46251-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T06:35:39Z","timestamp":1671258939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46251-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46251"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46251-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"20 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Vabanesi, Pisa, Guerrieri, Radaelli, Medaglini declare no competing interests relevant to the manuscript. Dr. Moiola received honoraria for speaking in scientific meetings and for advisory board from Biogen, Teva, Sanofi-Genzyme and Merck. Dr. Martinelli received honoraria for consulting services or speaking activity from Biogen, Merck, Novartis, Teva, Almirall, and Sanofi-Genzyme. Prof. Comi received personal compensation for consulting services and\/or speaking activities from Novartis, Teva, Sanofi, Sanofi-Genzyme, Merck, Biogen, Excemed, Serono Symposia International Foundation, Roche, Almirall, Receptos, Celgene, and Forward Pharma. Prof. Leocani received honoraria for consulting services and\/or speaking activity from Biogen, Novartis and Excemed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10371"}}